Anti-Hypertensive Drugs - Niger

Niger

The projected revenue for the Anti-Hypertensive Drugs market in Niger is expected to reach US$2.13m by 2024.
This market is anticipated to show an annual growth rate (CAGR 2024-2029) of 1.19%, resulting in a market volume of US$2.26m by 2029.
In comparison to other countries worldwide, United States is expected to generate the highest revenue in this market, with US$12,290.00m in 2024.
In Niger, the demand for anti-hypertensive drugs is steadily rising due to the increasing prevalence of hypertension among the population.

Key regions: Japan, India, Italy, Brazil, South Korea

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Hypertensive Drugs market in Niger has been experiencing significant growth in recent years.

Customer preferences: Niger has a high prevalence of hypertension, which has led to an increase in demand for Anti-Hypertensive Drugs. Patients in Niger prefer to use generic drugs due to their affordability.

Trends in the market: The Anti-Hypertensive Drugs market in Niger is dominated by imported drugs from India and China. However, there has been a recent trend towards locally manufactured drugs, which are becoming more popular due to their lower cost and availability. The market is also seeing an increase in the use of combination drugs, which offer a more effective treatment for hypertension.

Local special circumstances: Niger is a low-income country with a high burden of disease. The government has limited resources to invest in healthcare infrastructure and services. This has led to a reliance on foreign aid and donations to fund healthcare programs. The lack of investment in healthcare has also resulted in a shortage of healthcare professionals, which has affected the availability and quality of healthcare services in the country.

Underlying macroeconomic factors: Niger is one of the poorest countries in the world, with a low GDP per capita. The country's economy is heavily reliant on agriculture, which is vulnerable to climatic shocks and droughts. The government has limited resources to invest in healthcare and other social services, which has resulted in a lack of infrastructure and resources for healthcare. The high prevalence of hypertension in Niger has put a strain on the healthcare system, which is struggling to cope with the demand for Anti-Hypertensive Drugs.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.